Valuation : DMS

Market Cap 2.63Cr 3.06Cr 2.46Cr 2.25Cr 4.25Cr 292.66Cr 4.26Cr 29Cr 11Cr 147.5Cr 12Cr 11Cr 488.17Cr P/E 2026 *
33.8x
P/E 2027 * 10.2x
Enterprise Value 4.17Cr 4.86Cr 3.9Cr 3.58Cr 6.73Cr 464.01Cr 6.75Cr 46Cr 18Cr 233.86Cr 18Cr 18Cr 773.97Cr EV / Sales 2026 *
0.73x
EV / Sales 2027 * 0.52x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 3.06Cr
+1.30%-2.20%-21.41%+2.27% 1.29TCr
-0.14%-3.28%+20.78%+10.23% 450.8Cr
-0.21%-6.01%-44.16%-55.99% 122.9Cr
+2.96%-1.50%-37.93%-35.37% 115.76Cr
-0.42%+0.14%+17.54%+86.11% 111.85Cr
+3.30%-6.69%-41.06% - 105.43Cr
-0.32%-6.73%+40.23%+122.08% 52Cr
+4.98%+2.71%+53.28% - 29Cr
-2.22%-9.18%-66.78%+292.33% 25Cr
Average +0.92%-2.73%-8.83%+60.24% 255.46Cr
Weighted average by Cap. +1.00%-1.50%-12.32%+9.13%

Financials

2026 *2027 *
Net sales 5.68Cr 6.62Cr 5.32Cr 4.87Cr 9.17Cr 631.97Cr 9.2Cr 63Cr 25Cr 318.51Cr 25Cr 24Cr 1.05TCr 6.59Cr 7.68Cr 6.17Cr 5.65Cr 11Cr 733.22Cr 11Cr 73Cr 29Cr 369.54Cr 29Cr 28Cr 1.22TCr
Net income 8L 9L 7L 7L 12.92L 8.9Cr 12.96L 88.69L 34.67L 4.49Cr 34.99L 34.23L 15Cr 26L 30.29L 24.34L 22.29L 41.99L 29Cr 42.11L 2.88Cr 1.13Cr 15Cr 1.14Cr 1.11Cr 48Cr
Net Debt 1.54Cr 1.79Cr 1.44Cr 1.32Cr 2.49Cr 171.34Cr 2.49Cr 17Cr 6.67Cr 86Cr 6.74Cr 6.59Cr 285.8Cr 80L 93.2L 74.9L 68.58L 1.29Cr 89Cr 1.3Cr 8.87Cr 3.47Cr 45Cr 3.5Cr 3.42Cr 148.47Cr
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-